DNA Test Could Spare Two-Thirds of Breast Cancer Patients From Chemotherapy

A clinical trial spanning six countries and involving more than 4,000 women over 40 has produced evidence that could reshape how doctors treat breast cancer. The study, led by researchers at University College London, tested a genetic screening tool called Prosigna that reads the activity of 50 genes known to drive breast cancer growth. What they found was striking: more than two-thirds of the women in the trial could safely skip chemotherapy altogether without compromising their survival odds.

The Prosigna test works by generating a risk score based on tumor biology rather than the traditional clinical markers doctors have relied on for decades. Women classified as low-risk by the test received hormone therapy instead of chemotherapy. After five years, 93.7% of them remained cancer-free or alive—a survival rate nearly identical to the 94.9% seen in women who received chemotherapy as part of their treatment plan. The difference was not in outcomes but in what those women endured to get there.

Chemotherapy has long been the standard follow-up to surgery for many breast cancer patients because it reduces the risk of recurrence. But the treatment exacts a heavy price. Patients report severe fatigue, nausea, hair loss, compromised immune systems, and fertility damage that can reshape their lives for years. For women already facing the shock of a cancer diagnosis, the prospect of months of debilitating side effects looms large. The ability to identify which patients actually need chemotherapy—and which do not—could spare thousands from that ordeal.

Professor Rob Stein, who led the trial at the UCL Cancer Institute, framed the findings as a turning point toward what researchers call personalized medicine. Rather than applying a one-size-fits-all protocol based on age, tumor size, or other broad characteristics, doctors could now let the tumor's own genetic signature guide the decision. "For patients, this means many may be spared the physical and emotional burden of chemotherapy and its potential long-term side effects," Stein said. The shift is subtle in language but profound in practice: treatment tailored to biology instead of convention.

The implications ripple outward quickly. In England alone, the National Health Service treats roughly 5,000 breast cancer patients each year who could potentially avoid chemotherapy if these findings become standard practice. That is 5,000 women per year who might keep their hair, avoid the crushing fatigue, preserve their fertility, and maintain the immune strength their bodies need to heal. Multiply that across the six countries in the trial, and across the world, and the number of lives made materially better grows staggering.

The research does not suggest chemotherapy is unnecessary. For women at higher risk of recurrence—those whose tumors show aggressive genetic signatures—the treatment remains valuable and justified. What the trial demonstrates is that risk is not uniform, and neither should treatment be. A woman whose tumor biology suggests low recurrence risk does not need to sacrifice her quality of life for a marginal survival gain that may never materialize. The test makes that distinction visible and actionable.

What happens next depends on whether hospitals and health systems adopt the Prosigna test as routine practice. The evidence is strong, the logic is sound, and the human benefit is clear. But clinical trials and real-world implementation are different worlds. Doctors must be trained, laboratories must be equipped, and the test must be integrated into the decision-making process at the moment when women are most vulnerable and most likely to defer to authority. If that integration happens, the trial's promise could touch millions of lives. If it stalls in the gap between research and practice, it remains a finding that could have been.